In vitro, it has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc., and its mechanism is not fully understood. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, damaging viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often also has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a broad-spectrum antibiotic that has antibacterial effects on most Gram-negative and some Gram-positive bacteria. Its mechanism of action is to inhibit bacterial protein synthesis.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on cells and anaerobic microorganisms growing under hypoxic conditions. The metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death.

This product is a derivative of ibufenac, and its analgesic, anti-inflammatory and antipyretic effects are 2-2.5 times stronger than indomethacin and 26-50 times stronger than aspirin. The analgesic and anti-inflammatory effects of this product are achieved by inhibiting cyclooxygenase to reduce prostaglandins and also by inhibiting lipoxygenates to reduce the products of leukotrienes, bradykinin, etc.